3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Surgery
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Neoadjuvant Chemoimmunotherapy
1
Menstruation Disturbances
1
Leiomyoma
1
Invasive Breast Carcinoma
1
Endometriosis
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Adenomyosis
1
Interventions
Bevacizumab
37
Paclitaxel
33
Carboplatin
25
pembrolizumab
23
Specimen Handling
21
olaparib
19
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
liposomal doxorubicin
16
Cyclophosphamide
16
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Fulvestrant
9
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Disulfides
8
Doxorubicin
7
palbociclib
6
aldesleukin
6
Surveys and Questionnaires
6
Oxaliplatin
5
Letrozole
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Robotic Surgical Procedures
×
90 days
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled